|
|
Line 125: |
Line 125: |
| | valign=top | | | | valign=top | |
| {| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:32em" cellpadding="0" cellspacing="0"; | | {| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:32em" cellpadding="0" cellspacing="0"; |
| ! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Newborn, Age <1 Week}}'' | | ! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Basilar Skull Fracture}}'' |
| |- | | |- |
| ! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen'' | | ! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen'' |
| |- | | |- |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 50 mg/kg IV q8h''''' | | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30—60 mg/kg/day IV q8–12h''''' |
| |- | | |- |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND | | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND |
| |- | | |- |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 100—150 mg/kg/day IV q8—12h''''' | | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 8–12 g/day IV q4–6h'''''<BR> ''OR'' <BR> ▸ '''''[[Ceftriaxone]] 2 g IV q12h'''''<BR><BR> |
| |-
| | |} |
| ! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
| | {| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 50 mg/kg IV q8h'''''
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 2.5 mg/kg IV q12h'''''
| |
| |-
| |
| ! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Newborn, Age 1—4 Weeks}}''
| |
| |-
| |
| ! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 200 mg/kg/day IV q6—8h'''''
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 150—200 mg/kg/day IV q6—8h'''''
| |
| |-
| |
| ! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 200 mg/kg/day IV q6—8h'''''
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 2.5 mg/kg IV q8h''''' <BR> OR <BR> ▸ '''''[[Tobramycin]]2.5 mg/kg IV q8h''''' <BR> OR <BR> ▸ '''''[[Amikacin]] 10 mg/kg IV q8h'''''
| |
| |- | |
| ! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Infant and Children}}''<sup>†</sup>
| |
| |- | | |- |
| ! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 15 mg/kg IV q6h''''' <BR> to achieve serum trough concentrations of 15–20 μg/mL
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 225—300 mg/kg/day IV q6–8h''''' <BR>''OR''<BR> ▸'''''[[Ceftriaxone]] 80—100 mg/kg/day IV q12–24h''''' <BR> <BR> <BR> <BR>
| |
| |-
| |
| |}
| |
| | valign=top | | | | valign=top | |
| {| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:32em" cellpadding="0" cellspacing="0"; | | {| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:32em" cellpadding="0" cellspacing="0"; |
| ! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Adult, Age <50 Years}}<sup>†</sup>'' | | ! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Head Trauma; Post-Neurosurgery}}'' |
| |-
| |
| ! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30–60 mg/kg/day IV q8–12h''''' <BR> to achieve serum trough concentrations of 15–20 μg/mL
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 8–12 g/day IV q4–6h'''''<BR> ''OR'' <BR> ▸'''''[[Ceftriaxone]] 2 g IV q12h'''''
| |
| |-
| |
| ! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Adult, Age >50 Years}}''
| |
| |- | | |- |
| ! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen'' | | ! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen'' |
| |- | | |- |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30–60 mg/kg/day IV q8–12h''''' | | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30—60 mg/kg/day IV q8–12h''''' |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 2 g IV q4h'''''
| |
| |- | | |- |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND | | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND |
| |- | | |- |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 8–12 g/day IV q4–6h'''''<BR> ''OR'' <BR> ▸'''''[[Ceftriaxone]] 2 g IV q12h''''' | | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftazidime]] 2 g IV q8 h'''''<BR> ''OR''<BR>▸ '''''[[Cefepime]] 2 g IV q8h'''''<BR>▸ '''''[[Meropenem]] 2 g IV q8h''''' |
| |} | | |} |
|
| |
|
| ==References== | | ==References== |
| {{Reflist|2}} | | {{Reflist|2}} |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]
Medical Therapy
Empiric Treatment
- Adjunctive Dexamethasone (0.15 mg/kg IV q6h for 2—4 days) is recommended for both children and adult patients with acute bacterial meningitis.
Newborn, Age <1 Week
|
Preferred Regimen
|
▸ Ampicillin 50 mg/kg IV q8h
|
AND
|
▸ Cefotaxime 100—150 mg/kg/day IV q8—12h
|
Alternative Regimen
|
▸ Ampicillin 50 mg/kg IV q8h
|
AND
|
▸ Gentamicin 2.5 mg/kg IV q12h
|
Newborn, Age 1—4 Weeks
|
Preferred Regimen
|
▸ Ampicillin 200 mg/kg/day IV q6—8h
|
AND
|
▸ Cefotaxime 150—200 mg/kg/day IV q6—8h
|
Alternative Regimen
|
▸ Ampicillin 200 mg/kg/day IV q6—8h
|
AND
|
▸ Gentamicin 2.5 mg/kg IV q8h OR ▸ Tobramycin2.5 mg/kg IV q8h OR ▸ Amikacin 10 mg/kg IV q8h
|
Infant and Children†
|
Preferred Regimen
|
▸ Vancomycin 15 mg/kg IV q6h to achieve serum trough concentrations of 15–20 μg/mL
|
AND
|
▸ Cefotaxime 225—300 mg/kg/day IV q6–8h OR ▸Ceftriaxone 80—100 mg/kg/day IV q12–24h
|
|
|
†Add Ampicillin 2 g IV q4h (50 mg/kg IV q6h for children) if meningitis caused by Listeria monocytogenes is also suspected.
Adapted from Advances in treatment of bacterial meningitis. Lancet. 2012;380(9854):1693-702.[1]
Healthcare-Associated Meningitis